MIRA vs. NBRV, CASI, NXTC, OCUP, CLNN, EGRX, HCWB, AADI, DARE, and NRXP
Should you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Nabriva Therapeutics (NBRV), CASI Pharmaceuticals (CASI), NextCure (NXTC), Ocuphire Pharma (OCUP), Clene (CLNN), Eagle Pharmaceuticals (EGRX), HCW Biologics (HCWB), Aadi Bioscience (AADI), Daré Bioscience (DARE), and NRx Pharmaceuticals (NRXP). These companies are all part of the "pharmaceutical preparations" industry.
MIRA Pharmaceuticals (NASDAQ:MIRA) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, community ranking, dividends, earnings, profitability and institutional ownership.
35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, MIRA Pharmaceuticals had 3 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 4 mentions for MIRA Pharmaceuticals and 1 mentions for Nabriva Therapeutics. MIRA Pharmaceuticals' average media sentiment score of 0.58 beat Nabriva Therapeutics' score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.
Nabriva Therapeutics received 393 more outperform votes than MIRA Pharmaceuticals when rated by MarketBeat users.
MIRA Pharmaceuticals has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. MIRA Pharmaceuticals' return on equity of -293.51% beat Nabriva Therapeutics' return on equity.
MIRA Pharmaceuticals has higher earnings, but lower revenue than Nabriva Therapeutics. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
MIRA Pharmaceuticals beats Nabriva Therapeutics on 7 of the 12 factors compared between the two stocks.
Get MIRA Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MIRA Pharmaceuticals Competitors List
Related Companies and Tools
